tiprankstipranks
Trending News
More News >
BONESUPPORT HOLDING AB (SE:BONEX)
:BONEX
Sweden Market

BONESUPPORT HOLDING AB (BONEX) Earnings Dates, Call Summary & Reports

Compare
9 Followers

Earnings Data

Report Date
Apr 22, 2026
TBA (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
0.99
Last Year’s EPS
0.16
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 24, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: strong underlying sales growth (especially CERAMENT G in the U.S.), high gross margins, solid adjusted profitability and cash generation, plus continued geographic and product expansion (spine launch, De Novo path for CERAMENT V). Offsetting risks include currency translation headwinds that depressed reported growth, headwinds in Germany, rising commercial costs and distributor fees, newly introduced U.S. tariffs, and regulatory timing/uncertainty around CERAMENT V. Early-stage adoption in many newly opened accounts is still developing and some segments (spine, revision arthroplasty) require more evidence. Overall, the positives materially outweigh the challenges, with the company signaling confidence in 2026 constant-currency growth guidance (at least ~35%).
Company Guidance
BONESUPPORT guided 2026 to at least 35% sales growth in constant currencies (with little or no CERAMENT V sales baked into the base case, although FDA approval is expected around mid‑year following a De Novo pathway), while reiterating the strong Q4 baseline: net sales ~SEK 313m (reported growth 22% y/y; 36% at constant FX), adjusted operating result SEK 81m and adjusted operating margin ~26% (FX‑adjusted margin close to 27% vs 22.6% LY), reported operating result SEK 82m and operating cash flow SEK 54m. Key commercial metrics supporting the outlook include U.S. sales SEK 259m (≈40% CC growth), CERAMENT G U.S. quarter sales SEK 207m (vs SEK 154m prior year), antibiotic‑eluting CERAMENT +54% LTM at constant FX (LTM reported growth ~31%, ~40% CC), very high gross margin (~95%), selling & marketing spend SEK 128m (distributor commissions/fees SEK 85m), and the note that a newly introduced U.S. tariff (50%) will have a gradual ~0.8% full effect on U.S. gross margins by late 2026; management also flagged continued German market headwinds through 2026 and normalization in the U.K. as assumed in the guidance.
Strong Quarterly Revenue Growth
Net sales for Q4 reached ~SEK 312–313 million, up 22% year-over-year reported and up 36% at constant exchange rates. Last-12-month reported growth was ~31% (40% at constant FX). Antibiotic-eluting CERAMENT products grew ~54% LTM in constant currency.
CERAMENT G U.S. Momentum
CERAMENT G U.S. sales reached SEK 207 million in the quarter (versus SEK 154 million a year earlier). U.S. sales overall grew ~40% at constant exchange rates, driven by new accounts, wider adoption among existing accounts and improving sales per working day. Distribution expanded to >140 Level 1 trauma centers (from 15 at end-2024), establishing a strong launch footprint.
Healthy Profitability and Cash Generation
Adjusted operating result (ex long‑term incentive effects) was ~SEK 81 million, with an adjusted operating margin of ~26% (FX-adjusted margin ~27% vs 22.6% prior year). Reported operating result was ~SEK 81.8 million. Operating cash flow remained robust at SEK 54 million and gross margin stayed high at ~95% (minor decline noted).
Product and Market Expansion
Early-stage U.S. launch of CERAMENT BVF in spine was initiated. Regulatory work progressed as CERAMENT V U.S. submission was moved to the De Novo pathway (positioning the product for a distinct category). Europe & RoW sales of SEK 54 million showed 18% growth at constant FX; hybrid markets (Southern Europe, Australia, Canada) showed strong performance. India and Japan remain strategic market targets with India launch expected H1 2026.
Clinical & Access Progress
Broader clinical traction: expansion from foot & ankle into trauma and revision arthroplasty with encouraging pilot data (e.g., Charité) and collaborations (e.g., Oxford Bone Infection Unit). Investments in commercial programs (EUROW booster) and focused training/support are accelerating access and adoption.

BONESUPPORT HOLDING AB (SE:BONEX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SE:BONEX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 22, 2026
2026 (Q1)
0.98 / -
0.16
Feb 24, 2026
2025 (Q4)
0.88 / 0.67
0.82-18.90% (-0.15)
Oct 23, 2025
2025 (Q3)
0.80 / 0.52
0.46511.83% (+0.05)
Jul 15, 2025
2025 (Q2)
0.74 / 0.79
0.41789.45% (+0.37)
Apr 24, 2025
2025 (Q1)
- / 0.16
0.334-52.10% (-0.17)
Feb 25, 2025
2024 (Q4)
- / 0.82
0.165396.97% (+0.65)
Oct 24, 2024
2024 (Q3)
- / 0.47
3.516-86.77% (-3.05)
Jul 11, 2024
2024 (Q2)
- / 0.42
0.08421.25% (+0.34)
Apr 25, 2024
2024 (Q1)
- / 0.33
0.0056580.00% (+0.33)
Feb 15, 2024
2023 (Q4)
- / 0.17
-0.318151.89% (+0.48)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

SE:BONEX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 24, 2026
kr180.80kr187.40+3.65%
Oct 23, 2025
kr255.60kr238.40-6.73%
Jul 15, 2025
kr296.60kr311.60+5.06%
Apr 24, 2025
kr317.40kr306.40-3.47%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BONESUPPORT HOLDING AB (SE:BONEX) report earnings?
BONESUPPORT HOLDING AB (SE:BONEX) is schdueled to report earning on Apr 22, 2026, TBA (Confirmed).
    What is BONESUPPORT HOLDING AB (SE:BONEX) earnings time?
    BONESUPPORT HOLDING AB (SE:BONEX) earnings time is at Apr 22, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of BONESUPPORT HOLDING AB stock?
          The P/E ratio of BONESUPPORT HOLDING AB is N/A.
            What is SE:BONEX EPS forecast?
            SE:BONEX EPS forecast for the fiscal quarter 2026 (Q1) is 0.99.